Tradestie Institutional Equity Comparison Engine
SLS vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (2โ2 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while SLS counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLS trades at N/M Forward P/E with 0.0% operating margin (-82.5% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, SLS sits in BREAKOUT (27th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
SLS N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 0.0% vs 41.3% ยท YoY -82.5% vs +102.1%
Momentum & Technical Winner
SLS
1Y +1239.2% vs +23.2% ยท 52W Pos 76% vs 33%
Options & Structure Winner
SLS
BREAKOUT (27th %ile IV) vs BREAKDOWN (57th %ile IV)
SLS
NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$19.15
+156.36% 1D
Market Cap
$1.5B
1M Return
+82.55%
1Y Return
+1239.16%
Forward P/E
N/M
Unified AI Score
34.1 / 100
SELL
Tech 5.0
Fund 37.0
Flow 66.0
Mom 38.9
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
49.8 / 100
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SLS +1239.16%
CGEN +23.17%
Spread: +1215.99 pp (SLS Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SLS Revenue | CGEN Revenue | SLS Op. Margin | CGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2016 | N/A | $0M | N/A | -4576.3% | CGEN |
| FY2018 | N/A | $20M | N/A | -130.5% | CGEN |
| FY2020 | $0M | $0M | -893.8% | -1574.8% | SLS |
| FY2021 | $10M | $10M | -332.8% | -584.6% | SLS |
| FY2022 | $0M | $10M | -4195.0% | -471.7% | CGEN |
| FY2023 | N/A | $30M | N/A | -38.8% | CGEN |
| FY2024 | N/A | $30M | N/A | -53.4% | CGEN |
| FY2025 | N/A | $70M | N/A | 43.1% | CGEN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SLS | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5B | $193.2M | Larger Scale | SLS |
| Trailing P/E Ratio Valuation | N/M | 5.2x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | N/M | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | -82.5% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 0.0% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 0.0% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | -40.3% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 76% ($1โ$25) | 33% ($1โ$3) | Stronger Trend | SLS |
| Beta / 30D Volatility Risk Regime | 1.30ฮฒ ยท 544% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 34.1 / 100 (SELL) | 49.8 / 100 (HOLD) | Higher Composite | CGEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SLS vs CGEN Buy Guide
SLS
BREAKOUT
99d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
27th %ile
IV Regime
Balanced (25thโ60th %ile)
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SLS nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.